Sulfonylurea in the treatment of neonatal diabetes mellitus children with heterogeneous genetic backgrounds

Abstract

Our study showed that SU monotherapy resulted in satisfactory glycemic control in most of the patients with NDM whose genetic defects are heterogeneous. The usage of SU may be considered as first-line therapy for patients with NDM in developing countries where effective genetic screening is not established.